The Efficacy of Saccharomyces boulardii CNCM I-745 in Addition to Standard Helicobacter pylori Eradication Treatment in Children

Purpose This study aims to investigate Saccharomyces boulardii CNCM I-745 during Helicobacter pylori eradication in children. Methods One hundred ninety-four H. pylori positive children were randomized in two groups. Therapy (omeprazole+clarithromycin+amoxicillin or omeprazole+clarithromycin+metronidazole in case of penicillin allergy) was given to both groups during two weeks. In the treatment group (n: 102) S. boulardii was added to the triple therapy, while the control group (n: 92) only received triple therapy. The incidence, onset, duration and severity of diarrhea and compliance to the eradication treatment were compared. A 13C urea breath test was done 4 weeks after the end of eradication therapy in two groups of 21 patients aged 12 years and older to test the H. pylori eradication rate. Results In the treatment group, diarrhea occurred in 12 cases (11.76%), starting after 6.25±1.24 days, lasting 3.17±1.08 days, and compliance to eradication treatment was 100%. In the control group, diarrhea occurred in 26 cases (28.26%), starting after 4.05±1.11 days, lasting 4.02±0.87 days, and in six cases eradication treatment was stopped prematurely (p<0.05). The 13C urea breath test showed successful H. pylori eradication in 71.4% of the patients in the treatment and in 61.9 % in the control group (not significant). Conclusion S. boulardii has a beneficial effect on the prevention and treatment of diarrhea during H. pylori eradication in children. Although S. boulardii did only slightly increase H. pylori eradication rate, compliance to eradication treatment was improved.

• Publication year

  2015

• Venue

  Pediatric Gastroenterology Hepatology & Nutrition

• Publication date

  2015-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.5223/pghn.2015.18.1.17PMID 25866729PMCID 4391996
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Helicobacter pylori infection: host immune response, implications on gene expression and microRNAs.

  2014influential reference
• European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases Evidence-Based Guidelines for the Management of Acute Gastroenteritis in Children in Europe: Update 2014

  2014cited by this paper
• Evidence-Based Guidelines for the Management of Acute Gastroenteritis in Children in Europe : Update 2014

  2014cited by this paper
• Anti-Diarrheal Effects of Diosmectite in the Treatment of Acute Diarrhea in Children

  2012influential reference
• Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis.

  2011cited by this paper
• Evidence-based Guidelines From ESPGHAN and NASPGHAN for Helicobacter pylori Infection in Children

  2011cited by this paper
• Meta‐analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment

  2010cited by this paper
• Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.

  2010cited by this paper
• Mechanisms of action of probiotics: Recent advances

  2009cited by this paper
• Saccharomyces boulardii in childhood

  2009cited by this paper
• Helicobacter pylori infection in children: population‐based age‐specific prevalence and risk factors in a developing country

  2009cited by this paper
• Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era.

  2009cited by this paper
• A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children

  2009cited by this paper
• Effects of Saccharomyces boulardii on cytokine secretion from intraepithelial lymphocytes infected by Escherichia coli and Candida albicans

  2009cited by this paper
• Saccharomyces boulardii inhibits lipopolysaccharide‐induced activation of human dendritic cells and T cell proliferation

  2008cited by this paper
• Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: Influence of Saccharomyces boulardii.

  2008cited by this paper
• Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea.

  2008cited by this paper
• Saccharomyces boulardii Inhibits ERK1/2 Mitogen-activated Protein Kinase Activation Both in Vitro and in Vivo and Protects against Clostridium difficile Toxin A-induced Enteritis*

  2006cited by this paper
• Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes.

  2006cited by this paper
• H pylori and host interactions that influence pathogenesis.

  2006cited by this paper
• Helicobacter pylori extract induces nuclear factorkappa b, activator protein-1, and cyclooxygenase-2 in esophageal epithelial cells

  2006cited by this paper
• Efficacy and Safety of Helicobacter pylori Eradication Therapy with Omeprazole, Amoxicillin and High- and Low-Dose Clarithromycin in Japanese Patients

  2006cited by this paper
• Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori

  2005cited by this paper
• Maternal perception of excess weight in children: a survey conducted by paediatricians in the province of Milan.

  2005cited by this paper
• Cytokine Expression in Pediatric Helicobacter pylori Infection

  2005cited by this paper

• Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication of Helicobacter pylori: a meta-analysis

  2025cites this paper
• Health-Promoting and Functional Properties of Fermented Milk Beverages with Probiotic Bacteria in the Prevention of Civilization Diseases

  2024cites this paper
• Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis?

  2024cites this paper
• The Impact of Bioactive Molecules from Probiotics on Child Health: A Comprehensive Review

  2024cites this paper
• World Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics.

  2024cites this paper
• Saccharomyces boulardii combined with triple therapy alter the microbiota in the eradication of Helicobacter pylori infection

  2024cites this paper
• Gut dysbiosis mediates the association between antibiotic exposure and chronic disease

  2024cites this paper
• A SYSTEMATIC REVIEW OF THE TREATMENT OF HELICOBACTER PYLORI BY THE EFFECT OF PROBIOTICS IN ASIAN POPULATION

  2023cites this paper
• The effect of Saccharomyces boulardii supplementation on Helicobacter pylori eradication in children: a systematic review and meta-analysis of Randomized controlled trials

  2023cites this paper
• Combination of gastroprotectors and probiotics in the eradication of H. pylori infection: results of a randomized comparative clinical trial

  2023cites this paper
• Probiotics for the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications

  2022cites this paper
• Probiotics and gastrointestinal diseases.

  2022cites this paper
• Are pro- and/or synbiotics beneficial in Helicobacter pylori eradication therapy in children? A narrative review

  2022cites this paper
• [Systematic review: clinical evidence of probiotics in the prevention of antibiotic-associated diarrhoea].

  2021cites this paper
• Health-promoting properties of Saccharomyces cerevisiae var. boulardii as a probiotic; characteristics, isolation, and applications in dairy products

  2021cites this paper
• Klinische Evidenz zu Probiotika in der Prävention einer Antibiotika-assoziierten Diarrhö

  2021cites this paper
• Treatment of Helicobacter pylori infection in children: A systematic review

  2020cites this paper
• An overview of yeast probiotics as cancer biotherapeutics: possible clinical application in colorectal cancer

  2020cites this paper
• Probiotics for the prevention of antibiotic-associated adverse events in children – a systematic review to inform development of a core outcome set

  2020cites this paper
• Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases

  2020cites this paper
• Probiotics for the prevention of antibiotic-associated adverse events in children—A scoping review to inform development of a core outcome set

  2020influential citation
• Perspectives from the Society for Pediatric Research: Probiotic use in urinary tract infections, atopic dermatitis, and antibiotic-associated diarrhea: an overview

  2020cites this paper
• Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis with trial sequential analysis

  2019influential citation
• Developing a guide of bioinformatic database for probiotic products

  2019influential citation
• Infection and Drug Resistance Dovepress

  2019cites this paper
• Lactobacillus reuteri DSM 17938 in the prevention of antibiotic-associated diarrhoea in children: a randomized clinical trial.

  2019cites this paper
• Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial

  2019cites this paper
• Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruption

  2019cites this paper
• Probiotics for the prevention of pediatric antibiotic-associated diarrhea.

  2019cites this paper
• Clinical Efficacy Comparison of Saccharomyces Boulardii and Lactic Acid as Probiotics in Acute Pediatric Diarrhea.

  2018cites this paper
• Common Organisms and Probiotics: Saccharomyces boulardii

  2017cites this paper
• Probiotics in 14-day triple therapy for Asian pediatric patients with Helicobacter pylori infection: a network meta-analysis

  2017cites this paper
• Cellular and molecular effects of yeast probiotics on cancer

  2017cites this paper
• Lactobacillus reuteri DSM 17938 in the prevention of antibiotic-associated diarrhoea in children: protocol of a randomised controlled trial

  2017cites this paper
• Probiotics as an adjuvant treatment in Helicobacter pylori eradication therapy

  2017cites this paper
• Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis

  2017cites this paper
• Probiotics improve the efficacy of standard triple therapy in the eradication of Helicobacter pylori: a meta-analysis

  2016cites this paper
• Effect of topically applied Saccharomyces boulardii on the healing of acute porcine wounds: a preliminary study

  2016cites this paper
• Probiotics as Dietary Supplements for Eradication of Helicobacter pylori Infection in Children: A Role Beyond Infection

  2016cites this paper
• Analysis of the effects of microbiome-related confounding factors on the reproducibility of the volatolomic test

  2016cites this paper
• Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children.

  2016cites this paper
• Saccharomyces Boulardii in Helicobacter Pylori Eradication in Children: A Randomized Trial From Iran

  2016cites this paper
• Helicobacter pylori Infection in Pediatrics

  2015cites this paper
• Probiotics for the prevention of pediatric antibiotic-associated diarrhea.

  2015cites this paper
• Systematic review with meta‐analysis: Saccharomyces boulardii in the prevention of antibiotic‐associated diarrhoea

  2015cites this paper
• Use of probiotics in pediatric infectious diseases

  2015cites this paper